{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T11:26:26Z","timestamp":1788953186645,"version":"build-2803163510"},"reference-count":64,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T00:00:00Z","timestamp":1716163200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.pnpbp.2024.111031","type":"journal-article","created":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T10:13:02Z","timestamp":1715940782000},"page":"111031","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Peripheral serotonin levels as a predictor of antidepressant treatment response: A systematic review"],"prefix":"10.1016","volume":"133","author":[{"given":"Amanda","family":"Holck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Movahed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa","family":"Westrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen M.","family":"Wolkowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Lindqvist","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Asp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.pnpbp.2024.111031_bb0005","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1007\/s002130050924","article-title":"Plasma serotonin level after 1 day of fluoxetine treatment: a biological predictor for antidepressant response?","volume":"143","author":"Alvarez","year":"1999","journal-title":"Psychopharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111031_bb0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00213-022-06276-5","article-title":"Systematic review of studies using platelet serotonin content to assess bioeffect of serotonin reuptake inhibitors at the serotonin transporter","volume":"240","author":"Anderson","year":"2023","journal-title":"Psychopharmacology"},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111031_bb0015","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.bbagen.2012.05.012","article-title":"Correlation of serotonin levels in CSF, platelets, plasma, and urine","volume":"1820","author":"Audhya","year":"2012","journal-title":"Biochim. Biophys. Acta"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111031_bb0020","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1038\/s41398-019-0507-5","article-title":"Metabolomic signature of exposure and response to citalopram\/escitalopram in depressed outpatients","volume":"9","author":"Bhattacharyya","year":"2019","journal-title":"Transl. Psychiatry"},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111031_bb0025","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1373\/clinchem.2011.163824","article-title":"The measurement of platelet-poor plasma serotonin: a systematic review of prior reports and recommendations for improved analysis","volume":"57","author":"Brand","year":"2011","journal-title":"Clin. Chem."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111031_bb0030","first-page":"102","article-title":"Can serotonin and fluoxetine levels in plasma and platelets predict clinical response in depression?","volume":"37","author":"Castrogiovanni","year":"2003","journal-title":"Psychopharmacol. Bull."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111031_bb0035","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/0165-0327(92)90082-H","article-title":"Effects of acute and chronic treatment with fluvoxamine on extracellular and platelet serotonin in the blood of major depressive patients. Relationship to clinical improvement","volume":"25","author":"Celada","year":"1992","journal-title":"J. Affect. Disord."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111031_bb0040","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1097\/00004714-199210000-00003","article-title":"Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement","volume":"12","author":"Celada","year":"1992","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2024.111031_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2022.110608","article-title":"The ERICH3 rs11580409 polymorphism is associated with 6-month antidepressant response in depressed patients","volume":"119","author":"Chappell","year":"2022","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2024.111031_bb0050","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4137\/IJTR.S2097","article-title":"Kynurenine pathway metabolites in humans: disease and healthy states","volume":"2","author":"Chen","year":"2009","journal-title":"Int J Tryptophan Res"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111031_bb0055","doi-asserted-by":"crossref","first-page":"24226","DOI":"10.1038\/s41598-021-03753-3","article-title":"Interaction effect of serum serotonin level and age on the 12-week pharmacotherapeutic response in patients with depressive disorders","volume":"11","author":"Choi","year":"2021","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111031_bb0060","doi-asserted-by":"crossref","first-page":"248","DOI":"10.9758\/cpn.2022.20.2.248","article-title":"Associations of serum serotonin levels with 12-week and 12-month remission in patients with depressive disorders","volume":"20","author":"Choi","year":"2022","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"10.1016\/j.pnpbp.2024.111031_bb0065","series-title":"DSM-vol. 5","volume":"Vol. 5","author":"Diagnostic and Statistical Manual of Mental Disorders","year":"2013"},{"key":"10.1016\/j.pnpbp.2024.111031_bb0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.pnpbp.2020.110016","article-title":"Effect of vortioxetine vs. escitalopram on plasma BDNF and platelet serotonin in depressed patients","volume":"105","author":"Dvojkovic","year":"2021","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2024.111031_bb0075","first-page":"4","article-title":"Mechanism of action of antidepressant medications","volume":"60 Suppl 4","author":"Feighner","year":"1999","journal-title":"J. Clin. Psychiatry"},{"issue":"1\u20132","key":"10.1016\/j.pnpbp.2024.111031_bb0080","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jad.2008.10.014","article-title":"What happens to patients with treatment-resistant depression? A systematic review of medium to long term outcome studies","volume":"116","author":"Fekadu","year":"2009","journal-title":"J. Affect. Disord."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111031_bb0085","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0006-3223(98)00344-8","article-title":"Pretreatment platelet 5-HT concentration predicts the short-term response to paroxetine in major depression. Grupo de Trastornos Afectivos","volume":"46","author":"Figueras","year":"1999","journal-title":"Biol. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111031_bb0090","doi-asserted-by":"crossref","first-page":"E351","DOI":"10.25011\/cim.v31i6.4921","article-title":"Reduction of cerebrospinal fluid and plasma serotonin in patients with post-stroke depression: a preliminary report","volume":"31","author":"Gao","year":"2008","journal-title":"Clin. Invest. Med."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111031_bb0095","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/j.2051-5545.2011.tb00061.x","article-title":"The heterogeneity of \"major depression\"","volume":"10","author":"Goldberg","year":"2011","journal-title":"World Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111031_bb0100","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/0006-3223(94)00312-Q","article-title":"Neurochemistry and paroxetine response in major depression","volume":"37","author":"Goodnick","year":"1995","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111031_bb0105","first-page":"261","article-title":"Sertraline in coexisting major depression and diabetes mellitus","volume":"33","author":"Goodnick","year":"1997","journal-title":"Psychopharmacol. Bull."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111031_bb0110","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3109\/10401230009147095","article-title":"Nefazodone treatment of adolescent depression: an open-label study of response and biochemistry","volume":"12","author":"Goodnick","year":"2000","journal-title":"Ann. Clin. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111031_bb0115","article-title":"Metabolomics of major depressive disorder: a systematic review of clinical studies","volume":"14","author":"Guerreiro Costa","year":"2022","journal-title":"Cureus"},{"issue":"12","key":"10.1016\/j.pnpbp.2024.111031_bb0120","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/mp.2016.6","article-title":"TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics","volume":"21","author":"Gupta","year":"2016","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2024.111031_bb0125","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.pnpbp.2013.04.009","article-title":"Monoamine neurocircuitry in depression and strategies for new treatments","volume":"45","author":"Hamon","year":"2013","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111031_bb0130","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S2215-0366(17)30015-9","article-title":"How do antidepressants work? New perspectives for refining future treatment approaches","volume":"4","author":"Harmer","year":"2017","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2024.111031_bb0135","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jad.2019.02.063","article-title":"Plasma serotonin levels are associated with antidepressant response to SSRIs","volume":"250","author":"Holck","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2024.111031_bb0140","author":"International statistical"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111031_bb0145","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1177\/02698811231161813","article-title":"Fifty years on: serotonin and depression","volume":"37","author":"Jauhar","year":"2023","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2024.111031_bb0150","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.bbr.2017.12.025","article-title":"Understanding the pathophysiology of depression: from monoamines to the neurogenesis hypothesis model - are we there yet?","volume":"341","author":"Jesulola","year":"2018","journal-title":"Behav. Brain Res."},{"issue":"7","key":"10.1016\/j.pnpbp.2024.111031_bb0155","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0006-3223(96)00207-7","article-title":"Plasma free 3-methoxy-4-hydroxyphenylglycol predicts response to fluoxetine","volume":"41","author":"Ko","year":"1997","journal-title":"Biol. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111031_bb0160","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1600-0447.1992.tb10320.x","article-title":"Relationship between parameters of serotonin transport and antidepressant plasma levels or therapeutic response in depressive patients treated with paroxetine and amitriptyline","volume":"85","author":"Kuhs","year":"1992","journal-title":"Acta Psychiatr. Scand."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111031_bb0165","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/S0006-3223(97)00389-2","article-title":"Biological parameters in major depression: effects of paroxetine, viloxazine, moclobemide, and electroconvulsive therapy. Relation to early clinical outcome","volume":"44","author":"Lestra","year":"1998","journal-title":"Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111031_bb0170","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/s41398-020-01097-6","article-title":"Alterations in acylcarnitines, amines, and lipids inform about the mechanism of action of citalopram\/escitalopram in major depression","volume":"11","author":"MahmoudianDehkordi","year":"2021","journal-title":"Transl. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111031_bb0175","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1002\/hup.2525","article-title":"Evaluation of interleukin-6 and serotonin as biomarkers to predict response to fluoxetine","volume":"31","author":"Manoharan","year":"2016","journal-title":"Hum. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111031_bb0180","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/S0165-1781(98)00126-7","article-title":"Relationships between low red blood cell count and clinical response to fluoxetine in depressed elderly patients","volume":"81","author":"Mentre","year":"1998","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.pnpbp.2024.111031_bb0185","article-title":"The serotonin theory of depression: a systematic umbrella review of the evidence","author":"Moncrieff","year":"2022","journal-title":"Mol. Psychiatry"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2024.111031_bb0190","first-page":"57","article-title":"Modulating the serotonin system in the treatment of major depressive disorder","volume":"19","author":"Morrissette","year":"2014","journal-title":"CNS Spectr."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111031_bb0195","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/0165-0327(91)90028-Q","article-title":"Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients","volume":"23","author":"Muck-Seler","year":"1991","journal-title":"J. Affect. Disord."},{"issue":"7\u20138","key":"10.1016\/j.pnpbp.2024.111031_bb0200","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1016\/S0278-5846(02)00259-2","article-title":"The effects of paroxetine and tianeptine on peripheral biochemical markers in major depression","volume":"26","author":"Muck-Seler","year":"2002","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111031_bb0205","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1097\/00004714-199802000-00011","article-title":"Serotonin transporter-blocking properties of nefazodone assessed by measurement of platelet serotonin","volume":"18","author":"Narayan","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111031_bb0210","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0165-0327(93)90012-9","article-title":"Effects of the antidepressant drug tianeptine on plasma and platelet serotonin of depressive patients and healthy controls","volume":"29","author":"Ortiz","year":"1993","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2024.111031_bb0215","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.pnpbp.2024.111031_bb0220","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jad.2022.06.080","article-title":"C-reactive protein could predict the efficacy of SSRIs in clinical practice: a cohort study of large samples in the real world","volume":"313","author":"Pan","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111031_bb0225","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004714-199806000-00007","article-title":"Relationship between blood serotonergic variables, melancholic traits, and response to antidepressant treatments","volume":"18","author":"Perez","year":"1998","journal-title":"J. Clin. Psychopharmacol."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111031_bb0230","doi-asserted-by":"crossref","first-page":"193","DOI":"10.30773\/pi.2019.0289","article-title":"Personalized psychiatry and depression: the role of sociodemographic and clinical variables","volume":"17","author":"Perna","year":"2020","journal-title":"Psychiatry Investig."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111031_bb0235","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0278-5846(03)00105-2","article-title":"Long-term sertraline treatment and peripheral biochemical markers in female depressed patients","volume":"27","author":"Pivac","year":"2003","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111031_bb0240","doi-asserted-by":"crossref","first-page":"385","DOI":"10.31887\/DCNS.2008.10.4\/gracagni","article-title":"Cellular and molecular mechanisms in the long-term action of antidepressants","volume":"10","author":"Racagni","year":"2008","journal-title":"Dialogues Clin. Neurosci."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111031_bb0245","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/sj.mp.4001949","article-title":"Mood is indirectly related to serotonin, norepinephrine and dopamine levels in humans: a meta-analysis of monoamine depletion studies","volume":"12","author":"Ruhe","year":"2007","journal-title":"Mol. Psychiatry"},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111031_bb0250","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1001\/archpsyc.1978.01770300115013","article-title":"Research diagnostic criteria: rationale and reliability","volume":"35","author":"Spitzer","year":"1978","journal-title":"Arch. Gen. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111031_bb0255","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0165-0327(98)00221-3","article-title":"Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects","volume":"51","author":"Stahl","year":"1998","journal-title":"J. Affect. Disord."},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111031_bb0260","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1017\/S1092852900016965","article-title":"Monoamine oxidase inhibitors: a modern guide to an unrequited class of antidepressants","volume":"13","author":"Stahl","year":"2008","journal-title":"CNS Spectr."},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111031_bb0265","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/j.euroneuro.2015.06.007","article-title":"Inflammation and clinical response to treatment in depression: a meta-analysis","volume":"25","author":"Strawbridge","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111031_bb0270","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0024-3205(02)01828-3","article-title":"Intra- and inter-individual relationships between central and peripheral serotonergic activity in humans: a serial cerebrospinal fluid sampling study","volume":"71","author":"Strawn","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.pnpbp.2024.111031_bb0275","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.bbi.2020.01.011","article-title":"The relationship between plasma serotonin and kynurenine pathway metabolite levels and the treatment response to escitalopram and desvenlafaxine","volume":"87","author":"Sun","year":"2020","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111031_bb0280","doi-asserted-by":"crossref","DOI":"10.1002\/bmc.4135","article-title":"Analysis and measurement of serotonin","volume":"32","author":"Szeitz","year":"2018","journal-title":"Biomed. Chromatogr."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111031_bb0285","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111031_bb0290","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/0278-5846(90)90051-H","article-title":"The relationship between response to fluoxetine, plasma drug levels, imipramine binding to platelet membranes and whole-blood 5-HT","volume":"14","author":"Tyrer","year":"1990","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2024.111031_bb0295","series-title":"In","article-title":"Depression and other common mental disorders: Global Health estimates","author":"WHO","year":"2017"},{"key":"10.1016\/j.pnpbp.2024.111031_bb0300","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.jad.2019.03.008","article-title":"Potential serum biomarkers for the prediction of the efficacy of escitalopram for treating depression","volume":"250","author":"Xu","year":"2019","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.pnpbp.2024.111031_bb0305","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.jad.2022.02.069","article-title":"The association of C-reactive protein with responses to escitalopram antidepressant treatment in patients with major depressive disorder","volume":"306","author":"Zhou","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"7","key":"10.1016\/j.pnpbp.2024.111031_bb0310","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0068283","article-title":"Pharmacometabolomics of response to sertraline and to placebo in major depressive disorder - possible role for methoxyindole pathway","volume":"8","author":"Zhu","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2024.111031_bb0315","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ejphar.2018.07.033","article-title":"Platelet serotonin and serotonin transporter as peripheral surrogates in depression and anxiety patients","volume":"834","author":"Zhuang","year":"2018","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2024.111031_bb0320","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.comppsych.2014.09.007","article-title":"How many different ways do patients meet the diagnostic criteria for major depressive disorder?","volume":"56","author":"Zimmerman","year":"2015","journal-title":"Compr. Psychiatry"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858462400099X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S027858462400099X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T03:29:27Z","timestamp":1717298967000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S027858462400099X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":64,"alternative-id":["S027858462400099X"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2024.111031","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral serotonin levels as a predictor of antidepressant treatment response: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2024.111031","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"111031"}}